Abstract
Protein phosphatase 2A (PP2A) is a well-known tumor suppressor frequently inhibited in human cancer. Alterations affecting PP2A subunits together with the deregulation of endogenous PP2A inhibitors such as CIP2A and SET have been described as contributing mechanisms to inactivate PP2A in prostate cancer. Moreover, recent findings highlight that functional inactivation of PP2A could represent a key event in the acquisition of castration-resistant phenotype and a novel molecular target with high impact at both clinical and therapeutic levels in prostate cancer.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Apoptosis / genetics
-
Autoantigens / genetics
-
Autoantigens / metabolism*
-
Autoantigens / therapeutic use
-
Cell Proliferation / genetics
-
DNA-Binding Proteins
-
Gene Expression Regulation, Neoplastic
-
Histone Chaperones / genetics
-
Histone Chaperones / metabolism*
-
Histone Chaperones / therapeutic use
-
Humans
-
Intracellular Signaling Peptides and Proteins
-
Male
-
Membrane Proteins / genetics
-
Membrane Proteins / metabolism*
-
Membrane Proteins / therapeutic use
-
Molecular Targeted Therapy
-
Prostatic Neoplasms, Castration-Resistant / genetics*
-
Prostatic Neoplasms, Castration-Resistant / pathology
-
Prostatic Neoplasms, Castration-Resistant / therapy
-
Protein Phosphatase 2 / antagonists & inhibitors
-
Protein Phosphatase 2 / genetics*
-
Protein Phosphatase 2 / therapeutic use
-
Receptors, Androgen / metabolism
-
Transcription Factors / genetics
-
Transcription Factors / metabolism*
-
Transcription Factors / therapeutic use
Substances
-
Autoantigens
-
CIP2A protein, human
-
DNA-Binding Proteins
-
Histone Chaperones
-
Intracellular Signaling Peptides and Proteins
-
Membrane Proteins
-
Receptors, Androgen
-
SET protein, human
-
Transcription Factors
-
Protein Phosphatase 2